18 results
8-K
EX-99.1
PCSA
Processa Pharmaceuticals Inc
26 Jan 22
Processa Pharmaceuticals CEO Dr. David Young Issues Letter to Shareholders Providing Outlook for 2022
8:15am
recruitment efforts in the second half of 2021. Even with slower than expected enrollment, we should still meet our goal of initiating a Phase 3 pivotal … optimal PCS6422 DPD inhibition regimen. The revised protocol will be submitted to the FDA in the first quarter of 2022 with the plan to restart recruitment
424B3
PCSA
Processa Pharmaceuticals Inc
12 Apr 21
Prospectus supplement
1:44pm
Tumors, with recruitment beginning in the first half of 2021. PCS12852 has already been evaluated in clinical studies in South Korea and we anticipate
S-3
q0kznr4f9
2 Apr 21
Shelf registration
12:00am
424B4
urlz483ovnn aqq
29 Jan 24
Prospectus supplement with pricing info
4:15pm
- Prev
- 1
- Next